MARKET

DCPH

DCPH

Deciphera Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

52.35
-3.72
-6.63%
Closed 16:00 09/21 EDT
OPEN
54.88
PREV CLOSE
56.07
HIGH
54.89
LOW
52.02
VOLUME
402.92K
TURNOVER
--
52 WEEK HIGH
71.11
52 WEEK LOW
31.37
MARKET CAP
2.95B
P/E (TTM)
-10.1581
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
An Intrinsic Calculation For Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Suggests It's 48% Undervalued
How far off is Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) from its intrinsic value? Using the most recent financial...
Simply Wall St. · 1d ago
Deciphera Pharma's QINLOCK shows sustained benefit in gastrointestinal tumor
Deciphera Pharmaceuticals (DCPH) has announced nine month follow-up data from the Company’s Phase 3 INVICTUS study of QINLOCK in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors ((GIST)) and
Seekingalpha · 3d ago
Deciphera Presents Data from QINLOCK (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of nine month follow-up data from the Company’s Phase 3 INVICTUS study of QINLOCK in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors (GIST) and intra-patient dose escalation data from the ongoing
Business Wire · 3d ago
Deciphera Pharma Reports Will Present 9-Month Follow-Up Data From Phase 3 INVICTUS Study Of QINLOCK In Patients With Fourth-Line Gastrointestinal Stromal Tumors At European Society For Medical Oncology Meeting Sept. 19-21
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of nine month follow-up data from the Company’s Phase 3 INVICTUS study of QINLOCK in patients with fourth-line and fourth-line plus
Benzinga · 3d ago
Deciphera's rebastinib shows encouraging efficacy in ovarian cancer
Deciphera Pharmaceuticals (DCPH) announces data from the ovarian cancer cohort in Part 2 of the ongoing Phase 1b/2 study of rebastinib, the selective TIE2 inhibitor, in combination with paclitaxel and
Seekingalpha · 4d ago
Deciphera Presents Data from Rebastinib Its TIE2 Inhibitor Program At the European Society for Medical Oncology (ESMO) Virtual Congress 2020
- Rebastinib Combined with Paclitaxel Showed Encouraging Preliminary Clinical Benefit and Favorable Tolerability in Patients with Platinum-resistant Ovarian Cancer -  - Rebastinib Combined with Carboplatin was
Rebastinib Combined with Paclitaxel Showed Encouraging Preliminary Clinical Benefit and Favorable Tolerability in Patients with Platinum-resistant Ovarian Cancer -  - Rebastinib Combined with Carboplatin was · 4d ago
Hedge Funds Never Been This Bullish On Deciphera Pharmaceuticals, Inc. (DCPH)
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of June 30th, when the S&P 500 Index
Insider Monkey · 09/15 05:48
The Week Ahead In Biotech: Decision Day For Bausch Health, IPO Flow Resumes, Oncology Conference
Biotech stocks continued to remain under pressure in the week ended Sept. 11, swayed by the volatility that was evident in the broader market.
Benzinga · 09/13 13:49
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DCPH stock price target is 73.00 with a high estimate of 91.00 and a low estimate of 52.00.
EPS
Institutional Holdings
Institutions: 224
Institutional Holdings: 43.73M
% Owned: 77.57%
Shares Outstanding: 56.38M
TypeInstitutionsShares
Increased
66
5.48M
New
46
484.55K
Decreased
47
4.07M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.94%
Pharmaceuticals & Medical Research
-2.24%
Key Executives
Chairman/Independent Director
James Bristol
President/Chief Executive Officer/Director
Steven Hoerter
Founder/Executive Vice President/Chief Scientific Officer
Daniel Flynn
Chief Financial Officer/Executive Vice President/Treasurer
Thomas Kelly
Executive Vice President
Matthew Sherman
Director
Michael Taylor
Independent Director
Patricia Allen
Independent Director
Edward Benz
Independent Director
Frank Friedman
Independent Director
Susan Kelley
Independent Director
John Martin
Independent Director
Ron Squarer
Independent Director
Dennis Walsh
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average DCPH stock price target is 73.00 with a high estimate of 91.00 and a low estimate of 52.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About DCPH
Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally administered kinase switch control inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, including glioblastoma multiforme (GBM), and other solid tumors driven by pan-KIT or PDGFR alpha. DCC-3014 is an orally administered, potent and highly selective inhibitor of colony stimulating factor receptor 1 (CSF1R). Rebastinib is an orally administered, potent and selective inhibitor of the TIE2 immunokinase. Rebastinib binds potently into the switch pocket of TIE2, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Deciphera Pharmaceuticals Inc stock information, including NASDAQ:DCPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DCPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DCPH stock methods without spending real money on the virtual paper trading platform.